Gossamer Bio has disclosed that it has halted development of GB5121 and terminated all clinical studies of the drug following a partial clinical hold imposed by the FDA after two patients died in a Phase Ib/II trial.
Late breaker presentation at IDWeek 2022First double-blind registrational phase 3 study in Staphylococcus aureus bacteremiaCeftobiprole non-inferior to.